CONTACT
+91 80 2808 2808
info@biocon.com
Biocon  /  Businesses  /  Novel Biologics  /  Itolizumab

NOVEL PIPELINE

Itolizumab

The world’s first novel anti-CD6 monoclonal antibody

Itolizumab was launched in India in 2013 under the brand name ALZUMAb™. Itolizumab is Biocon’s second ‘lab to market’ novel biologic after Nimotuzumab and offers a ‘best-in-class’ biologic drug for acute psoriasis. ALZUMAb™ offers a less aggressive dosing regimen and a longer treatment free period and has seen encouraging outcomes. Our research also indicated Itolizumab’s potential in treating several autoimmune conditions.

Itolizumab has received emergency use approval in India to treat cytokine release syndrome in COVID-19 patients with moderate to severe acute respiratory distress syndrome.

null

ITOLIZUMAB

Scientific publications

Biocon Sponsored

Non Biocon Sponsored

Itolizumab approved for emergency use in Covid-19 in India

A pivotal study from Itolizumab significantly reduced mortality in moderate to severe ARDS (Acute Respiratory Distress Syndrome) patients hospitalised with COVID-19, in India.

View Peer-Reviewed Article on Itolizumab >>

Read More about Biocon’s fight against Covid-19 >>

Partnership with Equillium for Developing Itolizumab

Equillium, a U.S.-based clinical-stage biotechnology company, acquired rights for developing and commercializing Itolizumab in the U.S., Canada, Australia and New Zealand through an exclusive collaboration and license agreement with Biocon.

Biocon outlicensed Itolizumab to Equillium in 2017. Equillium is leveraging its deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company is developing Itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), lupus/lupus nephritis and uncontrolled asthma.

Equillium Press Releases

Read More >>

MOA of Itolizumab-Covid-19

Itolizumab MOA
Biocon Finance
FINANCIAL CALENDAR
KEY THERAPEUTIC AREAS
OUR KEY PRIORITIES
Siddharth Mittal
BOARD OF DIRECTORS
PRESS RELEASES
Share
Previous Next
Close
Test Caption
Test Description goes like this